On CNBC’s Mad Dash segment on Monday, July 6, 2026, Jim Cramer made one of his most bullish biotech calls in years, arguing ...
Fresh with a rebrand, Cyllene will advance gene therapies built on a platform that uses a modified form of the herpes virus ...
Vertex makes its largest-ever deal, skyrocketing health insurance costs, and more biotech news from The Readout ...
Vertex claimed the two drugs in the deal could eventually bring in more than $5 billion annually. Still, the high price it ...
Vertex Pharmaceuticals is buying an endocrine treatment specialist for $10 billion.
Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial intelligence (AI) solution company for brain disorders ...
Delve into the hidden innovation system of drug repurposing. When patents expire and commercial value fades, a new wave of ...
Founded by MIT-Trained Scientists, Biotech Startup Advances Predictive AI to Improve Human Safety Assessment, Reduce Costly Drug Attrition and Accelerate Drug Development BOSTON, MA / ACCESS Newswire ...
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging ...
Eupraxia Pharmaceuticals Inc. ('Eupraxia' or the 'Company') (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize ...
Obesity-focused clinical-stage biotechnology company Kalohexis on Tuesday confidentially filed to go public in the U.S., adding to an activity rebound in the initial public offering market.
Following an independent salary analysis, this landmark certification sets a benchmark for data-driven pay equity and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results